Torilis japonica extract fraction compound, EGFR-targeted inhibition of cancer abnormal metastasis in A549 lung cancer cells

Kim,Guen Tae; Kim,Sang-Yong; Kim,Young Min

doi:10.3892/or.2017.5771

Torilis japonica extract fraction compound, EGFR-targeted inhibition of cancer abnormal metastasis in A549 lung cancer cells

Authors:
- Guen Tae Kim
- Sang-Yong Kim
- Young Min Kim
View Affiliations

Affiliations: Department of Biological Sciences, College of Life Science and Nanotechnology, Hannam University, Yuseong-gu, Daejeon, Republic of Korea, Department of Food Science and Biotechnology, Shinansan University, Ansan-city, Gyeonggi-do, Republic of Korea
Published online on: June 30, 2017 https://doi.org/10.3892/or.2017.5771
Pages: 1206-1212

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The number of patients who die from lung cancer is steadily increasing. According to the 2012 statistics, lung cancer accounts for the highest percentage of death from cancer in both sexes. Many research studies found that lung cancer can be caused not only by smoking but by outdoor pollution, and it leads to over-activation of various surface proteins in cancer cells. The over-activity of epidermal growth factor receptor (EGFR) is implicated as a crucial factor in inducing abnormal metastasis of lung cancer cells. In this study, we investigated the inhibitory effect of Torilis japonica extract (TJE) major fraction compound in A549 lung cancer cells by inhibiting EGFR activity. We confirmed that inhibitory effect of TJE on the abnormal metastasis using invasion assay and 3D cell culture method, as well as the inhibition of EGFR signaling pathway, co-binding with Stat3 and dimer formation for translocation to the nucleus. We confirmed the EGFR targets inhibition of TJE when compared with EGFR knockdown group using siRNA transfection. The CAM assay confirmed once again the efficacy of the TJE. We suggest that TJE is a new potential reagent for EGFR-targeted therapy and anti-abnormal metastasis in A549 lung cancer cells.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Mathers CD, Fat DM, Inoue M, Rao C and Lopez AD: Counting the dead and what they died from: An assessment of the global status of cause of death data. Bull World Health Organ. 83:171–177. 2005.PubMed/NCBI
3	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global Cancer Statistics. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
4	Hamra GB, Guha N, Cohen A, Laden F, Raaschou-Nielsen O, Samet JM, Vineis P, Forastiere F, Saldiva P, Yorifuji T, et al: Outdoor particulate matter exposure and lung cancer: A systematic review and meta-analysis. Environ Health Perspect. 122:906–911. 2014.PubMed/NCBI
5	Straif K, Cohen A and Samet J: Air Pollution and Cancer. IARC Scientific Publication No. 161 Lyon: IARC Press; https://www.iarc.fr/en/publications/books/sp161/AirPollutionandCancer161.pdf
6	International Agency for Research on Cancer: Personal Habits and Indoor Combustions. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 100E. Lyon: IARC Press; http://monographs.iarc.fr/ENG/Monographs/vol100E/mono100E.pdf
7	Líbalová H, Krčková S, Uhlířová K, Kléma J, Ciganek M, Rössner P Jr, Šrám RJ, Vondráček J, Machala M and Topinka J: Analysis of gene expression changes in A549 cells induced by organic compounds from respirable air particles. Mutat Res. 770:94–105. 2014. View Article : Google Scholar : PubMed/NCBI
8	Krishnan VG, Ebert PJ, Ting JC, Lim E, Wong SS, Teo AS, Yue YG, Chua HH, Ma X, Loh GS, et al: Whole-genome sequencing of Asian lung cancers: Second-hand smoke unlikely to be responsible for higher incidence of lung cancer among Asian never-smokers. Cancer Res. 74:6071–6081. 2014. View Article : Google Scholar : PubMed/NCBI
9	Alper O, Bergmann-Leitner ES, Bennett TA, Hacker NF, Stromberg K and Stetler-Stevenson WG: Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst. 93:1375–1384. 2001. View Article : Google Scholar : PubMed/NCBI
10	Ahmed N, Maines-Bandiera S, Quinn MA, Unger WG, Dedhar S and Auersperg N: Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Am J Physiol Cell Physiol. 290:C1532–C1542. 2006. View Article : Google Scholar : PubMed/NCBI
11	Siegelin MD and Borczuk AC: Epidermal growth factor receptor mutations in lung adenocarcinoma. Lab Invest. 94:129–137. 2014. View Article : Google Scholar : PubMed/NCBI
12	Yeom SY, Nam DH and Park C: RRAD promotes EGFR-mediated STAT3 activation and induces temozolomide resistance of malignant glioblastoma. Mol Cancer Ther. 13:3049–3061. 2014. View Article : Google Scholar : PubMed/NCBI
13	Hipp S, Walch A, Schuster T, Losko S, Laux H, Bolton T, Höfler H and Becker KF: Activation of epidermal growth factor receptor results in snail protein but not mRNA overexpression in endometrial cancer. J Cell Mol Med. 13:3858–3867. 2009. View Article : Google Scholar : PubMed/NCBI
14	Anupama EG, Oliver B and Khatri L: Nuclear signaling of EGFR and EGFRvIII in glioblastoma. Molecular Targets of CNS tumors. Garami M: Croatia: InTech, Rijeka; 2011, https://www.scribd.com/document/112167777/Molecular-Targets-of-CNS-Tumors
15	Gong C, Zhang Y, Shankaran H and Resat H: Integrated analysis reveals that STAT3 is central to the crosstalk between HER/ErbB receptor signaling pathways in human mammary epithelial cells. Mol Biosyst. 11:146–158. 2015. View Article : Google Scholar : PubMed/NCBI
16	Lo HW, Hsu SC, Ali-Seyed M, Gunduz M, Xia W, Wei Y, Bartholomeusz G, Shih JY and Hung MC: Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell. 7:575–589. 2005. View Article : Google Scholar : PubMed/NCBI
17	Kim GT, Lee SH and Kim YM: Torilis japonica extract, a new potential EMT suppressor agent by regulation of EGFR signaling pathways. Int J Oncol. 45:1673–1679. 2014.PubMed/NCBI
18	Brand TM, Iida M, Luthar N, Starr MM, Huppert EJ and Wheeler DL: Nuclear EGFR as a molecular target in cancer. Radiother Oncol. 108:370–377. 2013. View Article : Google Scholar : PubMed/NCBI
19	Liu L, McBride KM and Reich NC: STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proc Natl Acad Sci USA. 102:8150–8155. 2005. View Article : Google Scholar : PubMed/NCBI
20	Michael V, Tamas D, Dzina K, Swen L, Anne S, Valeria P, Walter R and Gerhard MN: The role of the N-terminal domain in dimerization and nucleocytoplasmic shutting of latent STAT3. J Cell Sci. 124:900–909. 2010.
21	Wang SC and Hung MC: Nuclear translocation of the epidermal growth factor receptor family membrane tyrosine kinase receptors. Clin Cancer Res. 15:6484–6489. 2009. View Article : Google Scholar : PubMed/NCBI
22	Lo HW, Hsu SC and Hung MC: EGFR signaling pathway in breast cancers: From traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat. 95:211–218. 2006. View Article : Google Scholar : PubMed/NCBI